Biljana Obrenović-Kirćanski, Bojana Orbović, Mile Vraneš, Biljana Parapid, Nataša Kovačević-Kostić, Miloš Velinović, Stana Ristić
Index: Srp. Arh. Celok. Lek. 140(7-8) , 521-7, (2012)
Full Text: HTML
Atrial fibrillation occurs as a frequent complication after cardiac interventions. It can be found in 5% of all surgical patients, and it is far more common in cardiac (10% - 65% of patients) than in non-cardiac procedures. In a number of patients it remains asymptomatic, but may be accompanied by very severe symptoms of hypotension, heart failure, syncope, systemic or pulmonary embolism, perioperative myocardial infarction, cerebrovascular insult and increased operative mortality. Patients whose postoperative course is complicated by atrial fibrillation require longer hospitalization. Possible predisposing factors of this arrhythmia are numerous and are associated with surgery, extensive coronary heart disease and revascularization, and preoperative diseases. According to the recommendations of the European Society of Cardiology orally applied beta-blocker, amiodarone and sotalol can be used for prophylaxis of atrial fibrillation. Following the recommendations, treatment of postoperative atrial fibrillation should include beta-blockers, amiodarone, and in patients with heart failure and left ventricular dysfunction, digoxin. Due to the increased risk of stroke, an anticoagulant protection is necessary. Many studies have been conducted with results supporting the prophylactic use of amiodarone and beta-blockers, while the treatment with new agents such as magnesium, statins, omega-3 fatty acids and inhibitors of the renin-angiotensin-aldosterone system is still being investigated.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Sotalol hydrochloride
CAS:959-24-0 |
C12H21ClN2O3S |
A pharmacologically validated, high-capacity, functional tha...
2010-12-01 [Assay Drug Dev. Technol. 8 , 714-26, (2010)] |
Resting heart rate and physical activity as risk factors for...
2013-12-01 [Heart 99(23) , 1755-60, (2013)] |
Antiarrhythmic drug use in patients <65 years with atrial fi...
2015-02-01 [Am. J. Cardiol. 115(3) , 316-22, (2015)] |
In vitro model for assessing arrhythmogenic properties of dr...
2012-01-01 [Cell Physiol. Biochem. 29(5-6) , 819-32, (2012)] |
Characterization of A-935142, a hERG enhancer, in the presen...
2012-04-20 [Life Sci. 90(15-16) , 607-11, (2012)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved